Research Article
PDF EndNote BibTex RIS Cite

Effect of Covid-19 Pandemic on Patients Undergoing Definitive Chemoradiotherapy

Year 2022, Volume 44, Issue 3, 247 - 251, 01.10.2022
https://doi.org/10.7197/cmj.1173087

Abstract

Lung cancer is frequently seen in patients who smoke, who are elderly, and who have more comorbid diseases. The risk of being affected by the Covid-19 pandemic is high in these patients. Here, we aimed to determine the effectiveness of the definitive chemoradiotherapy (CRT) in patients with non metastatic Non-Small Cell Lung Cancers (NSCLC) during the pandemic period. Patients with NSCLCs, between 2020-2022 were evaluated retrospectively. Treatment responses were evaluated and prognostic factors were investigated. Twenty-eight patients (70%) were men and twelve (30%) were women. Twenty-five (62.5%) patients had comorbidities. All of patients complated their treatments. Objective response rate was 72.5%. Respectively, 72.5% of patients had partial response, 27.5% of patients had stable disease. 92.5% of patients had a reduction in primary tumor, 42.5% had lymph nodes and 75% had a reduction in stage. Seven (17.5%) patients developed Covid-19. Passing a Covid-19 was decreased survival (p=0.012). In conclusion; High response rates have been obtained with CRT treatment applied to NSCLC patients during the Covid-19 pandemic period. Covid-19 infection significantly reduced survival in NSCLC patients receiving definitive CRT. 

References

  • Reference1 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72: 7-33.
  • Reference2 Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. J Travel Med 2020; 27: taaa008.
  • Reference3 Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar;21(3):335-337.
  • Reference4 Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 138-55.
  • Reference5 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.
  • Reference6 Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010; 28: 3739-45.
  • Reference7 Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28: 2181-90.
  • Reference8 Łazar-Poniatowska M, Bandura A, Dziadziuszko R, Jassem J. Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review). Transl Lung Cancer Res 2021; 10: 2018-31.
  • Reference9 Yilmaz U, Yılmaz U, Yasar Z, Kıraklı EK, Ulger S, Ozdogan Y, Demirci NY, Erol S, Ozdogan I, Sahin B, Koksal D, Akcay C. Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience. J Cancer Res Ther 2016; 12: 334-9.
  • Reference10 Käsmann L, Eze C, Taugner J, Roengvoraphoj O, Dantes M, Schmidt-Hegemann NS, Schiopu S, Belka C, Manapov F. Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol 2020;15: 167.

Year 2022, Volume 44, Issue 3, 247 - 251, 01.10.2022
https://doi.org/10.7197/cmj.1173087

Abstract

References

  • Reference1 Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72: 7-33.
  • Reference2 Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. J Travel Med 2020; 27: taaa008.
  • Reference3 Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar;21(3):335-337.
  • Reference4 Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 138-55.
  • Reference5 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.
  • Reference6 Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, Hida T, Kawahara M, Takeda K, Katakami N, Sawa T, Yokota S, Seto T, Imamura F, Saka H, Iwamoto Y, Semba H, Chiba Y, Uejima H, Fukuoka M. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010; 28: 3739-45.
  • Reference7 Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28: 2181-90.
  • Reference8 Łazar-Poniatowska M, Bandura A, Dziadziuszko R, Jassem J. Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review). Transl Lung Cancer Res 2021; 10: 2018-31.
  • Reference9 Yilmaz U, Yılmaz U, Yasar Z, Kıraklı EK, Ulger S, Ozdogan Y, Demirci NY, Erol S, Ozdogan I, Sahin B, Koksal D, Akcay C. Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience. J Cancer Res Ther 2016; 12: 334-9.
  • Reference10 Käsmann L, Eze C, Taugner J, Roengvoraphoj O, Dantes M, Schmidt-Hegemann NS, Schiopu S, Belka C, Manapov F. Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol 2020;15: 167.

Details

Primary Language English
Subjects Health Care Sciences and Services
Journal Section Medical Science Research Articles
Authors

Elanur KARAMAN> (Primary Author)
MEDICAL PARK KARADENIZ HOSPITAL
0000-0002-4264-8214
Türkiye


Arife ULAŞ>
Bursa City Hospital
0000-0003-2918-2592
Türkiye

Publication Date October 1, 2022
Published in Issue Year 2022, Volume 44, Issue 3

Cite

APA Karaman, E. & Ulaş, A. (2022). Effect of Covid-19 Pandemic on Patients Undergoing Definitive Chemoradiotherapy . Cumhuriyet Medical Journal , 44 (3) , 247-251 . DOI: 10.7197/cmj.1173087